Adrenomedullin disrupts insulin signaling in blood vessels, leading to systemic insulin resistance in obesity-associated type 2 diabetes.
Uniphar is expanding its footprint with new facilities in the United States and elsewhere to better support pharma and medtech manufacturers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback